Correlation Between Morgan Stanley and Ono Pharmaceutical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Ono Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Ono Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Morgan Stanley Direct and Ono Pharmaceutical Co, you can compare the effects of market volatilities on Morgan Stanley and Ono Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Ono Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Ono Pharmaceutical.

Diversification Opportunities for Morgan Stanley and Ono Pharmaceutical

0.28
  Correlation Coefficient

Modest diversification

The 3 months correlation between Morgan and Ono is 0.28. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and Ono Pharmaceutical Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ono Pharmaceutical and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with Ono Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ono Pharmaceutical has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Ono Pharmaceutical go up and down completely randomly.

Pair Corralation between Morgan Stanley and Ono Pharmaceutical

Given the investment horizon of 90 days Morgan Stanley Direct is expected to under-perform the Ono Pharmaceutical. But the stock apears to be less risky and, when comparing its historical volatility, Morgan Stanley Direct is 5.77 times less risky than Ono Pharmaceutical. The stock trades about -0.01 of its potential returns per unit of risk. The Ono Pharmaceutical Co is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  1,084  in Ono Pharmaceutical Co on December 27, 2024 and sell it today you would earn a total of  35.00  from holding Ono Pharmaceutical Co or generate 3.23% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy41.67%
ValuesDaily Returns

Morgan Stanley Direct  vs.  Ono Pharmaceutical Co

 Performance 
       Timeline  
Morgan Stanley Direct 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Morgan Stanley Direct has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Morgan Stanley is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors.
Ono Pharmaceutical 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Over the last 90 days Ono Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly weak essential indicators, Ono Pharmaceutical reported solid returns over the last few months and may actually be approaching a breakup point.

Morgan Stanley and Ono Pharmaceutical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Morgan Stanley and Ono Pharmaceutical

The main advantage of trading using opposite Morgan Stanley and Ono Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Ono Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ono Pharmaceutical will offset losses from the drop in Ono Pharmaceutical's long position.
The idea behind Morgan Stanley Direct and Ono Pharmaceutical Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges